Genmab A/S (NASDAQ:GMAB) Shares Bought by NEOS Investment Management LLC

NEOS Investment Management LLC grew its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 91.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 78,683 shares of the company's stock after buying an additional 37,533 shares during the quarter. NEOS Investment Management LLC's holdings in Genmab A/S were worth $1,642,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Genmab A/S by 3,049.3% during the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after buying an additional 394,670 shares in the last quarter. Two Sigma Advisers LP boosted its position in Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after purchasing an additional 280,900 shares in the last quarter. ABC Arbitrage SA acquired a new position in shares of Genmab A/S in the 4th quarter valued at $3,692,000. AIMZ Investment Advisors LLC purchased a new stake in Genmab A/S during the fourth quarter worth $3,525,000. Finally, Raymond James Financial Inc. acquired a new stake in Genmab A/S during the fourth quarter valued at $2,463,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

GMAB traded up $0.35 on Thursday, reaching $19.17. 626,005 shares of the company's stock were exchanged, compared to its average volume of 969,329. The stock has a market cap of $12.69 billion, a PE ratio of 11.02, a P/E/G ratio of 2.65 and a beta of 0.98. Genmab A/S has a twelve month low of $18.48 and a twelve month high of $30.50. The stock's fifty day moving average price is $20.76 and its 200-day moving average price is $21.71.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on GMAB shares. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a report on Thursday, February 13th. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.